Clinical trials: CVD - Cardiovascular Disease
Multiple Myeloma
A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the safety and the tolerability of siltuximab up to 11.0 mg/kg in combination with bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT01309412
- Testing
- Siltuximab
- Where
- 5 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Janssen Pharmaceutical K.K.
Multiple Myeloma
Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma
The purpose of this study is to determine the safety, tolerability, maximum tolerated dose (MTD), and recommended phase 2 dose (RP2D) in phase 1 and to determine the combined response rate of clinical response CR and very good…
- Trial name
- NCT01383928
- Testing
- Ixazomib, Lenalidomide, Dexamethasone
- Where
- 20 sites in United States
- Volunteers
- 64 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Wounds
The Use of CureXcellTM in a Community Setting for the Treatment of Hard to Heal Wounds
The primary objective of the study is to define procedures for the use of CureXcellTM in the community through Clalit Health Services.
- Trial name
- NCT01113307
- Testing
- Activated allogeneic white blood cells
- Where
- 7 sites in Israel
- Volunteers
- 131 people
- Sponsor
- Macrocure Ltd.
Hypertension
Cozaar XQ Re-examination Study (MK-0954-349)
This survey is conducted for preparing application material for re-examination under the Pharmaceutical Affairs Law and its Enforcement Regulation; its aim is to reconfirm the clinical usefulness of COZAAR XQ through collecting…
- Trial name
- NCT01041807
- Testing
- amlodipine/losartan
- Volunteers
- 669 people
- Sponsor
- Organon and Co
Hypertension
Using Telmisartan Alone or Combination of Telmisartan -HCTZ in the Treatment of Mild to Moderate Essential Hypertension
The aim of this therapeutic observation is to demonstrate the efficacy and safety of telmisartan or telmisartan and HCTZ in the treatment of patients with mild-to-moderate essential hypertension under normal conditions of use…
- Trial name
- NCT00638911
- Volunteers
- 33,247 people
- Sponsor
- Boehringer Ingelheim
Multiple Myeloma
PRospective Multiple Myeloma Impact Study
This will be a prospective, case-only, study to measure the impact of MMprofiler on treatment intention decisions in Multiple Myeloma patients.
- Trial name
- PROMMIS (NCT02911571)
- Testing
- MMprofiler SKY92 gene signature
- Where
- 9 sites in United States
- Volunteers
- 250 people
- Sponsor
- SkylineDx
Wide Neck Bifurcation Intracranial Aneurysms
Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device
A prospective, multicenter, single arm, interventional study. The target patient population for this study are adult subjects with WNBAs of the anterior and posterior intracranial circulation.
- Trial name
- WEB PAS (NCT04839705)
- Testing
- WEB
- Where
- 27 sites in United States
- Volunteers
- 195 people
- Sponsor
- Microvention-Terumo, Inc.
Multiple Myeloma
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.
- Trial name
- NCT03110822
- Testing
- Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone
- Where
- 13 sites in United States
- Volunteers
- 134 people
- Sponsor
- Oncotherapeutics
Mitral Valve Regurgitation
Mitral Valve Replacement With MValve Dock and Lotus
This study evaluates the MValve mitral prosthesis in conjunction with a Lotus transcatheter heart valve (THV) for mitral valve replacement in subjects at high risk for conventional mitral valve replacement or repair surgery.
- Trial name
- DOCK 1 (NCT02719912)
- Testing
- mitral valve replacement
- Where
- 4 sites in Brazil, France and 2 more
- Volunteers
- 30 people
- Sponsor
- MValve Technologies Ltd
Refractory Angina Pectoris, Ischemic Heart Disease
Cardiac Shock Wave Treatment in Patients With Reduced Coronary Flow Reserve
The purpose of the study is to assess the feasibility of Cardiac Shock Wave Treatment in patients with anginal chest pain and evidence of abnormal myocardial perfusion under stress in the absence of significant stenoses of the…
- Conditions
- Refractory Angina Pectoris, Ischemic Heart Disease, Coronary Artery Disease
- Trial name
- NCT03438500
- Testing
- Cardiac Extracorporeal Shockwave Therapy (Modulith SLC)
- Where
- Germany
- Sponsor
- Storz Medical AG
Stroke
Clinical Trial of Robot-assisted-gait-training (RAGT) in Stroke Patients
A clinical trial of robot-assisted-gait-training (RAGT) in stroke patients to evaluate its efficacy, safety over conventional gait training.
- Trial name
- Walkbot (NCT02694302)
- Testing
- Walkbot, Conventional physical therapy
- Where
- 2 sites in South Korea
- Volunteers
- 91 people
- Sponsor
- P&S Mechanics Co., Ltd.
Coronary Artery Disease
Post Marketing Clinical Trial to Demonstrate the Performance of the MedHub AutocathFFR Device.
Patients with suspected coronary artery disease who are scheduled to undergo a coronary angiography procedure will be enrolled in the study.
- Trial name
- NCT04724057
- Testing
- AutocathFFR
- Volunteers
- 488 people
- Sponsor
- Medhub Ltd.
Hypertension
A Study of TAK-536 in Children From 2 to Less Than 6 Years Old With High Blood Pressure
The main aim of this study is to check the safety of TAK-536. This study will take place in Japan. At the first visit, the study doctor will check if each child can take part.
- Trial name
- NCT04668157
- Testing
- TAK-536
- Where
- 19 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Takeda
ST Elevation Myocardial Infarction
Effect of DLBS1033 After Primary PCI in Patients With STE-ACS
This is a prospective, randomized, double-blind, double-dummy, and controlled clinical study over a total of 4-week therapy with DLBS1033 in the management of STE-ACS after a primary PCI.
- Trial name
- NCT02976701
- Testing
- DLBS1033, Standard therapy
- Where
- Indonesia
- Volunteers
- 23 people
- Sponsor
- Dexa Medica Group
ICD, Sudden Cardiac Death
Ability of Home Monitoring® to Detect and Manage the Inappropriate Diagnoses in Implantable Cardioverter Defibrillators.
The purpose of the THORN registry is to show the ability of Home-Monitoring® to early identify and manage the inappropriate diagnoses of ventricular arrhythmia in ICD patients (i.e.
- Conditions
- ICD, Sudden Cardiac Death, Ventricular Fibrillation, Atrial Fibrillation
- Trial name
- THORN (NCT01594112)
- Where
- 55 sites in France
- Volunteers
- 512 people
- Sponsor
- Biotronik SE & Co. KG
Hypertension, Diabetic Nephropathy
A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril
The purpose of this study is to evaluate the efficacy of valsartan, benazepril or the combination of both in reduction of microalbuminuria in Type 2 diabetic patients.
- Trial name
- NCT00171119
- Testing
- valsartan
- Where
- Switzerland
- Volunteers
- 81 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Hypertension
Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)
The primary objectives of this study are to assess the safety/tolerability and efficacy (by evaluating changes in pulmonary vascular resistance [PVR] and pulmonary blood volume [PBV]) of frespaciguat in participants with…
- Trial name
- NCT04370873
- Testing
- Frespaciguat
- Where
- 9 sites in United States, Israel and 1 more
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma
Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Primary Objectives: To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV) To assess the safety and tolerability (including local injection site tolerability) of…
- Trial name
- NCT04045795
- Testing
- isatuximab SAR650984 IV, pomalidomide, dexamethasone
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 56 people
- Sponsor
- Sanofi
Multiple Myeloma
Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
The purpose of this Phase II study is to evaluate the safety and effectiveness (good and bad effects) of carfilzomib given as a 30-minute infusion and at a dose of 70 mg/m2 to treat patients with multiple myeloma (MM), who are…
- Trial name
- NCT02294357
- Testing
- Carfilzomib, Dexamethasone, Prednisone
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Oncotherapeutics
Coronary Artery Disease
CYPHERTM Stent Post-Marketing Surveillance Registry (US-PMS)
The purpose of this PMS registry, named e-CYPHER Stent Registry, is to collect post marketing surveillance data on the CYPHERTM Sirolimus-eluting Coronary Stent following marketing approval, when used in normal clinical practice…
- Trial name
- NCT00245401
- Testing
- CYPHERTM Sirolimus-Eluting Coronary Stent
- Volunteers
- 2,070 people
- Sponsor
- Cordis US Corp.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.